Amyloid- (A) has been proposed as a biomarker and a drug target for the therapy of Alzheimer's disease (AD). The neurotoxic entity and relevance of each conformational form of A to AD pathology is still under debate; A oligomers are considered the major killer form of the peptide whereas monomers have been proposed to be involved in...
-
2018 (v1)PublicationUploaded on: April 14, 2023
-
2017 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2017 (v1)Publication
The mechanism of tau toxicity is still unclear. Here we report that recombinant tau oligomers and monomers, intraventricularly injected in mice with a pure human tau background, foster tau pathology through different mechanisms. Oligomeric forms of tau alter the conformation of tau in a paired helical filament-like manner. This effect occurs...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Neuroinflammation is involved in the pathogenesis of Alzheimer's disease, and the transcription factor NF-κB is a player in this event. We found here that the ischemic damage alone or in association with Aβ1-42 activates the NF-κB pathway, induces an increase of BACE1 and a parallel inhibition of Uch-L1 and TREM2, both in vitro and in vivo, in...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
It is now established that cholesterol oxidation products (oxysterols) are involved in several events underlying Alzheimer's disease (AD) pathogenesis. Of note, certain oxysterols cause neuron dysfunction and degeneration but, recently, some of them have been shown also to have neuroprotective effects. The present study, which aimed to...
Uploaded on: April 14, 2023 -
2016 (v1)Publication
The mechanistic relationship between amyloid β1-42 (Aβ1-42) and the alteration of Tau protein are debated. We investigated the effect of Aβ1-42 monomers and oligomers on Tau, using mice expressing wild-type human Tau that do not spontaneously develop Tau pathology. After intraventricular injection of Aβ1-42, mice were sacrificed after 3 h or...
Uploaded on: March 27, 2023